结直肠癌细胞系蛋白质组可代表原发肿瘤并预测药物敏感性
研究对44株结直肠癌细胞系进行蛋白质组与转录组分析,并与95例原发结直肠癌及60例正常组织比较,整合基因组与药物敏感性数据。细胞系蛋白质组可再现原发肿瘤的蛋白质异常及5种蛋白质组亚型,但存在间质、外源信号及生长条件所致系统差异;蛋白质组数据预测药物敏感性的效用优于基因组或转录组数据。
要点
- 结直肠癌细胞系蛋白质组可代表原发肿瘤的固有程序及蛋白质组亚型。
- 细胞系与原发肿瘤蛋白质组存在间质、外源信号及生长条件所致系统差异。
- 蛋白质组数据预测药物敏感性的效用优于基因组或转录组数据。
核心结论
- 已建立的结直肠癌细胞系蛋白质组可代表原发肿瘤。
- 蛋白质组数据预测药物敏感性的效用倾向于优于基因组和转录组谱。
- 整合蛋白质基因组分析凸显蛋白质组谱用于个体化癌症医学的潜力。
研究设计与样本
- 对44株结直肠癌细胞系进行蛋白质组和转录组分析,并与95例原发结直肠癌及60例正常组织比较,整合基因组与药物敏感性数据。
主要发现
- 细胞系再现原发肿瘤的蛋白质异常,尤其对固有程序。
- 细胞系再现肿瘤中蛋白质表达与DNA拷贝数畸变的关系及转录后调控特征。
- 肿瘤中先前识别的5种蛋白质组亚型在细胞系中均有体现。
- 细胞系与肿瘤蛋白质组存在系统差异,归因于间质、外源信号和生长条件。
- 肿瘤间质的贡献掩盖了在超突变表型细胞系中识别的DNA错配修复特征。
关键数值与推荐
- 全局蛋白质组数据预测已知药物靶点关系和整体药物敏感性优于基因组或转录组测量。
- 抑制与药物反应相关的可靶向蛋白进一步识别了相应的协同或拮抗药物组合。
临床怎么用
- 原文未据此给出推荐。
局限性
- 细胞系与肿瘤蛋白质组存在系统差异,归因于间质、外源信号和生长条件。
- 肿瘤间质的贡献掩盖了在超突变表型细胞系中识别的DNA错配修复特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Proteomics holds promise for individualizing cancer treatment. We analyzed to what extent the proteomic landscape of human colorectal cancer (CRC) is maintained in established CRC cell lines and the utility of proteomics for predicting therapeutic responses. METHODS: Proteomic and transcriptomic analyses were performed on 44 CRC cell lines, compared against primary CRCs (n=95) and normal tissues (n=60), and integrated with genomic and drug sensitivity data. RESULTS: Cell lines mirrored the proteomic aberrations of primary tumors, in particular for intrinsic programs. Tumor relationships of protein expression with DNA copy number aberrations and signatures of post-transcriptional regulation were recapitulated in cell lines. The 5 proteomic subtypes previously identified in tumors were represented among cell lines. Nonetheless, systematic differences between cell line and tumor proteomes were apparent, attributable to stroma, extrinsic signaling, and growth conditions. Contribution of tumor stroma obscured signatures of DNA mismatch repair identified in cell lines with a hypermutation phenotype. Global proteomic data showed improved utility for predicting both known drug-target relationships and overall drug sensitivity as compared with genomic or transcriptomic measurements. Inhibition of targetable proteins associated with drug responses further identified corresponding synergistic or antagonistic drug combinations. Our data provide evidence for CRC proteomic subtype-specific drug responses. CONCLUSIONS: Proteomes of established CRC cell line are representative of primary tumors. Proteomic data tend to exhibit improved prediction of drug sensitivity as compared with genomic and transcriptomic profiles. Our integrative proteogenomic analysis highlights the potential of proteome profiling to inform personalized cancer medicine.
引用
- Wang J, Mouradov D, Wang X, et al. Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity. Gastroenterology. 2017. PMID: 28625833. doi:10.1053/j.gastro.2017.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。